Part of: FDA Enforcement by Industry
TL;DR
- Food enforcement runs on a different statutory base than drug or device CGMP: much of it traces to the Food Safety Modernization Act (FSMA) and, for imported ingredients specifically, the Foreign Supplier Verification Program (FSVP) requirement under 21 CFR Part 1, Subpart L.
- Argus HQ's own tracking noted 4 separate FSVP Warning Letters issued by the Office of Inspections and Investigations in a six-week span in mid-2026, centered on supplier-verification documentation gaps rather than contamination findings at the U.S. facility itself, with Vivot LLC as one example.
- Seafood Hazard Analysis and Critical Control Point (HACCP) violations and Listeria/Salmonella contamination findings have appeared regularly through 2026, with letters to facilities including Full Fresh Produce LLC (April 2026) and J&B Food Consulting (March 2026).
- FSVP citations are procedurally distinct from contamination-based food citations: an FSVP finding can exist even where FDA has no evidence any imported ingredient was actually unsafe — the violation is a documentation and verification-process failure, not necessarily a product-safety one.
Why food enforcement needs its own framework, not a CGMP lens
Food and Drug Administration enforcement in the food sector doesn't map cleanly onto the CGMP-and-CFR-subsection framework that dominates drug and device Warning Letters. Much of food enforcement instead traces to the Food Safety Modernization Act (FSMA), a 2011 statute that restructured FDA's food-safety authority around prevention rather than response, and to its various implementing regulations — of which the Foreign Supplier Verification Program is one of the most consequential for companies that import ingredients rather than growing or raising everything domestically.
What FSVP actually requires
The Foreign Supplier Verification Program, under 21 CFR Part 1, Subpart L, requires U.S. importers of food to verify that their foreign suppliers are producing food in a manner that meets applicable U.S. safety standards. This is fundamentally a documentation and process obligation: an importer has to have an actual verification program in place — supplier audits, hazard analyses, documented review processes — not simply a good-faith belief that its foreign suppliers are safe. FSVP citations, when they occur, typically address gaps in this verification documentation and process, which is a meaningfully different kind of finding than a citation alleging actual contamination was found in a specific product.
The 2026 FSVP enforcement pattern
Argus HQ's own tracking identified 4 separate FSVP Warning Letters issued by FDA's Office of Inspections and Investigations within a six-week span in mid-2026, with Vivot LLC as one example (argushq.ai homepage sample brief, accessed 2026-07-16). What's notable about this cluster of letters, per that same tracking, is that they centered on supplier-verification documentation gaps rather than on contamination findings at the U.S. facility itself. That distinction matters for how a company should read its own exposure: an importer with a genuinely clean safety record — no contamination ever found in any shipment — can still receive an FSVP Warning Letter if its verification documentation and process don't meet the regulatory standard, because the violation being cited is the absence or inadequacy of the verification program, not evidence of an actual unsafe product.
Seafood HACCP and contamination-based citations, a separate track
Running alongside the FSVP pattern, and procedurally distinct from it, is a more conventional contamination-and-process-failure enforcement track centered on seafood Hazard Analysis and Critical Control Point (HACCP) requirements and general food-safety findings. Letters to facilities including Full Fresh Produce LLC (April 2026) and J&B Food Consulting (March 2026), tracked in Argus HQ's live feed, fall into this category — findings closer in character to the contamination and process-control citations more familiar from drug and device enforcement, even though the specific regulatory framework (HACCP requirements for seafood, general FSMA preventive-controls requirements for other foods) differs from CGMP.
Why the FSVP/contamination distinction matters for risk assessment
A food company evaluating its own FDA enforcement risk needs to assess two largely independent exposures, not one combined "food safety risk." An importer with excellent supplier relationships and genuinely safe imported ingredients can still be cited under FSVP if its documented verification process doesn't meet the regulatory standard — this is a compliance-process risk, correctable through better documentation and audit practices, independent of whether any actual safety problem exists. A domestic or seafood-specific manufacturer faces a separate exposure tied to HACCP and general preventive-controls compliance, which is closer to a conventional contamination-and-process-failure risk. A company that imports ingredients and also manufactures domestically is exposed on both tracks simultaneously, and a compliance program built to address one doesn't automatically address the other.
What this means for a food company's compliance program
- Treat FSVP compliance as a documentation and process obligation, separate from ingredient safety itself. A company can have a genuinely safe supply chain and still be cited if its verification program's documentation doesn't meet the regulatory standard.
- Seafood HACCP and general contamination-based citations run on a different track from FSVP. A company should not assume clean FSVP documentation covers exposure on the HACCP or general preventive-controls side, or vice versa.
- Importers face compounding exposure that domestic-only manufacturers don't. Any company sourcing ingredients internationally should treat FSVP documentation as an independent compliance workstream, not a subset of general food-safety practice.
- A single-day or single-batch pattern (like the 4-letter FSVP cluster in a six-week span) can signal FDA is running a targeted enforcement sweep, not issuing isolated, unrelated citations. Companies with a similar fact pattern to a competitor's recent citation should treat that as an early warning, consistent with the sub-wave enforcement pattern the pillar documents elsewhere in the industry.
Related reading
- FDA Enforcement by Industry — the pillar this spoke expands on.
- Why did FDA cite nine OTC drug manufacturers on three continents the same day? — a comparable sub-wave enforcement pattern in a different industry.
Sources
- Argus HQ homepage stats and live feed, argushq.ai, accessed 2026-07-16 — source of the FSVP cluster and Vivot LLC, Full Fresh Produce LLC, and J&B Food Consulting examples.
Argus HQ is informational only. Summaries are AI-assisted and may contain errors, misclassifications, or omissions. The underlying FDA Warning Letters are public records; always verify against the original source before regulatory decisions. Not legal, financial, or medical advice.